Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Pear Therapeutics logo — The leader in Prescription Digital Therapeutics

Pear Therapeutics

The leader in Prescription Digital Therapeutics

Founded 2013 United States Boston, United States 36 employees Post-IPO Equity Total: $409.00M Biotechnology, Digital Health +2

General Information

Company Name Pear Therapeutics
Founded Year 2013
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 36
Industries Biotechnology, Digital Health, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Pear Therapeutics. To contact Pear Therapeutics, visit peartherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pear Therapeutics compare?

A PDF of Pear Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pear Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pear Therapeutics

Pear Therapeutics is a leading company in the Prescription Digital Therapeutics industry. It is the parent company of Pear Therapeutics (US), Inc., traded on Nasdaq as PEAR. The company specializes in developing and commercializing software-based medicines known as prescription digital therapeutics (PDTs). With a vision to enhance patient outcomes, provide advanced engagement tools for clinicians, and offer cost-effective solutions for payers, Pear aims to redefine care through clinically validated software-based therapeutics. Moreover, Pear prides itself on having the first end-to-end platform for discovering, developing, and delivering PDTs, along with a robust pipeline of therapeutic products and candidates. Pear has successfully launched three PDTs with disease treatment claims recognized by the FDA. Its product, reSET®, designed for the treatment of substance use disorder, secured the distinction of being the first PDT to receive marketing authorization from the FDA for disease treatment. Subsequently, its second product, reSET-O®, developed for treating opioid use disorder, obtained Breakthrough Designation, further highlighting Pear's innovative capabilities. Additionally, Pear's third product, Somryst®, targeting chronic insomnia, became the first PDT to undergo simultaneous review through the FDA's Software Precertification Pilot Program and the traditional 510(k) pathway. Established in 2013, Pear Therapeutics is headquartered in the United States and operates within the sectors of Biotechnology, Digital Health, Health and Wellness, and Pharmaceutical. The company recently received a $125.00M Post-IPO Equity investment on 06 December 2021, with notable investors including Pilot House Ventures, Temasek Holdings, QUAD Investment Management, Sarissa Capital, SoftBank Vision Fund, TrustBridge Partners, The Eleven Fund, Shanda Group, Pritzker/Vlock Family Office, and Palantir Capital. For more information, visit Pear at www.peartherapeutics.com.

Business keywords: digital therapeutics, prescription digital therapeutics, software-based medicine, FDA-approved PDTs, substance use disorder treatment, opioid use disorder treatment, chronic insomnia treatment, clinical validation, patient outcomes, clinician engagement, payer solutions, Nasdaq listed company, innovative healthcare solutions

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $125.00M 10
Pilot House Ventures Temasek Holdings QUAD Investment Management
Pilot House Ventures, Temasek Holdings +8
06 Dec 2021
Series D $20.00M -
01 Mar 2021
Series D $80.00M 10
EDBI Novartis Pilot House Ventures
EDBI, Novartis +8
08 Dec 2020
Debt Financing $50.00M 1
Perceptive Advisors
Perceptive Advisors
07 Jul 2020
Series C $64.00M 9
Arboretum Ventures EDBI 5AM Ventures
Arboretum Ventures, EDBI +7
04 Jan 2019
Series B $50.00M 8
Arboretum Ventures EDBI 5AM Ventures
Arboretum Ventures, EDBI +6
02 Jan 2018
Series A $20.00M 5
Arboretum Ventures 5AM Ventures Novartis
Arboretum Ventures, 5AM Ventures +3
03 Feb 2016
Venture Round Undisclosed 1
5AM Ventures
5AM Ventures
19 Mar 2015

Latest News

View All
Biofourmis reaches unicorn status with $300M Series D — Mobihealthnews.com
Biofourmis reaches unicorn status with $300M Series D
Mobihealthnews.com Nov 23, 2025

Pear Therapeutics Alternatives & Competitors

View All Alternatives
Pear Therapeutics vs
Orexo AB publ
Orexo AB publ Sweden

Improves lives for patients suffering from mental illness and substance use disorder 💚

Post-IPO Debt
97 employees
Biotechnology, Health Care
Compare Pear Therapeutics vs Orexo AB publ
Pear Therapeutics vs
Tesu Health
Tesu Health United Kingdom

Evidence-based digital therapeutics platform for personalised management of chronic diseases.

3 employees
Biotechnology, Digital Health
Compare Pear Therapeutics vs Tesu Health
Pear Therapeutics vs
WellnessWits
WellnessWits United States

WellnessWits Delivers Care Through Collective Lived Experiences and Recovery (C.L.E.A.R) Groups

Seed
6 employees
Care Economy, Digital Health
View all alternatives

FAQ About Pear Therapeutics

The leader in Prescription Digital Therapeutics
Pear Therapeutics was founded in 2013.
Pear Therapeutics is headquartered in Boston, United States.
Pear Therapeutics operates in Biotechnology, Digital Health, Health and Wellness and Pharmaceutical. Its work centres on digital therapeutics, prescription digital therapeutics, software-based medicine and FDA-approved PDTs.
Pear Therapeutics has approximately 36 employees.
Pear Therapeutics has completed 8 funding rounds, raising a total of $409.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Pear Therapeutics include Orexo AB publ, Tesu Health, WellnessWits, Newel Health, Y-mAbs Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pear Therapeutics and Orexo AB publ are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pear Therapeutics, https://bouncewatch.com/company/pear-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout